Fig. 6

[¹¹¹In]In-DTPA-IRDye 800CW anti-CD64 can be used to image CD64 in implanted inflamed human RA synovium. [¹¹¹In]In-DTPA-IRDye 800CW anti-CD64 or [¹¹¹In]In-DTPA-IRDye 800CW isotype (10 µg/mouse) were injected in SCID mice implanted with RA synovium. A Representative USPECT-CT showing the uptake of [¹¹¹In]In-DTPA-IRDye 800CW anti-CD64 in the implanted synovium 48 h after antibody injection. B Representative optical images (IVIS) showing the uptake of [¹¹¹In]In-DTPA-IRDye 800CW anti-CD64 in the implanted synovium 48 h after antibody injection (left; whole mice with open skin and Right: organs). C Biodistribution of [¹¹¹In]In-DTPA-IRDye 800CW anti-CD64 and [.¹¹¹In]In-DTPA-IRDye 800CW isotype 48 h and 72 h after injection (n = 4–5 mice/group). D The synovium-to-blood ratio is higher for the anti-CD64 antibody compared to the isotype at 48 h and 72 h. E The signal of the anti-CD64 antibody (3 µg/mouse) at 48 h was blocked by co-injecting an excess (190-fold) of unlabeled anti-CD64 antibody (n = 7–8 synovium explants/group). Bar graphs depict mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001